Company Filing History:
1 out of 25 
1 out of 15 Years Active: 2023
Title: Ju Yuel Baek: Innovator in Antibody-Drug Conjugates
Introduction
Ju Yuel Baek is a prominent inventor based in Daejeon, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of antibody-drug conjugates (ADCs). His innovative work focuses on targeting ROR1, a protein associated with various diseases, including cancer.
Latest Patents
Ju Yuel Baek holds a patent for an "Antibody-drug conjugate comprising antibody against human ROR1 and use for the same." This invention relates to new ADCs that target ROR1, including methods for their preparation and applications in treating illnesses associated with the over-expression of ROR1. The patent emphasizes the potential of these ADCs in the production of drugs aimed at preventing and treating diseases, particularly cancer.
Career Highlights
Throughout his career, Ju Yuel Baek has worked with notable companies in the biotechnology sector. He has been associated with Legochem Biosciences, Inc. and Abl Bio Inc., where he has contributed to advancing research and development in therapeutic solutions.
Collaborations
Ju Yuel Baek has collaborated with esteemed colleagues, including Yun-Hee Park and Ho Young Song. These partnerships have fostered innovation and have been instrumental in the progress of his research endeavors.
Conclusion
Ju Yuel Baek's work in developing antibody-drug conjugates represents a significant advancement in cancer treatment. His innovative approach to targeting ROR1 has the potential to lead to new therapeutic options for patients.